The GSTZ1 Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. This loss-of-function model features targeted disruption of the GSTZ1 gene, encoding glutathione S-transferase zeta 1, without isolation of individual clones. The polyclonal format preserves population-level genetic diversity while ensuring consistent ablation of GSTZ1 protein expression across the bulk culture. This product is suited for functional studies requiring a heterogeneous knockout background rather than a clonal isolate, enabling robust analysis of GSTZ1-dependent processes.
Host A-549 cells originate from the lung adenocarcinoma of a 58-year-old Caucasian male and are widely employed as an epithelial model for non-small cell lung cancer (NSCLC). These adherent cells retain key characteristics of lung adenocarcinoma, including epithelial morphology and oncogenic signaling profiles. Their use in preclinical research spans drug sensitivity testing, metabolic profiling, and invasion studies. The A-549 background provides a clinically relevant platform for investigating genes implicated in tumor metabolism, drug resistance, and cancer progression.
GSTZ1 encodes a glutathione-dependent isomerase catalyzing the conversion of maleylacetoacetate to fumarylacetoacetate, the penultimate step in tyrosine catabolism. This reaction channels tyrosine-derived carbons into the tricarboxylic acid cycle as fumarate and acetoacetate. GSTZ1 functions as a homodimer and also exhibits dehalogenase activity toward dichloroacetate. Its transcription is regulated by HNF4?? and NRF2, with dietary tyrosine and phenylalanine levels acting as modulators. The tyrosine degradation pathway proceeds through tyrosine, homogentisate, maleylacetoacetate, fumarylacetoacetate, and fumarylacetoacetate hydrolase (FAH).
In the A-549 lung adenocarcinoma model, GSTZ1 knockout ablates the canonical tyrosine degradation pathway, leading to accumulation of maleylacetoacetate and other upstream intermediates. This metabolic block disrupts cellular energy homeostasis and redox balance, given the role of fumarate in mitochondrial respiration. The knockout also eliminates GSTZ1-mediated dehalogenation of dichloroacetate, a compound under investigation for metabolic cancer therapy. Consequently, this model is valuable for studying metabolite-driven stress responses, altered drug metabolism, and potential compensatory pathway activation in NSCLC.
Researchers can employ the GSTZ1 knockout A-549 polyclonal cells to investigate tyrosine metabolism in lung cancer using LC-MS-based metabolite profiling and maleylacetoacetate isomerase activity assays. The model enables exploration of GSTZ1??s role in chemoresistance through viability and apoptosis assays upon treatment with tyrosine pathway?Crelevant drugs or dichloroacetate. Functional studies of migration and invasion can be coupled with gene expression analysis by RT-qPCR or western blotting. This product is also suitable for toxicological assessments of halogenated compounds and for identifying synthetic lethal interactions with tyrosine catabolism defects. For further details, contact Ascent Research.
